Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer Therapies

Hosted by Joe Varriale

June 30, 2022



Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted cancer supportive care (TCSC) pharmaceutical company dedicated to the development of treatments to address specific side effects of cancer therapies- to improve the quality of life and outcomes for patients fighting cancer. Prior to founding OnQuality, she worked as a Physician-Scientist in numerous medical affairs and leadership roles at the NIH, Bristol-Myers Squibb, Astellas Pharma, Dendreon, and Juno Therapeutics. She studied medicine at Guangzhou University and studied pharmacology at the University of Texas-San Antonio.

In this episode, we discuss OnQuality’s clinical pipeline of TCSC drugs, the field of medical affairs, the inspiration we draw to pursue science and medicine, and the role of clinical conferences.


Listen here: https://podcasts.apple.com/us/podcast/hong-tang-targeting-the-common-side-effects-of/id1514696421?i=1000568262295